

1 **AlbaTraDIS: Comparative analysis of large datasets from parallel**
2 **transposon mutagenesis experiments**

3

4

5 Andrew J. Page¹, Sarah Bastkowski^{*1}, Muhammad Yasir¹, A. Keith Turner¹, Thanh Le Viet¹,
6 George M. Savva¹, Mark A. Webber^{1,2}, Ian G. Charles^{1,2}

7

8 ¹Quadram Institute Bioscience, Norwich Research Park, Colney Lane, Norwich, NR4 7UQ, UK.

9 ²University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK.

10

11

12 *Corresponding author: sarah.bastkowski@quadram.ac.uk

13

14

15 Abstract

16 Background

17 Bacteria have evolved over billions of years to survive in a wide range of environments.
18 Currently, there is an incomplete understanding of the genetic basis for mechanisms
19 underpinning survival in stressful conditions, such as the presence of anti-microbials.
20 Transposon mutagenesis has been proven to be a powerful tool to identify genes and
21 networks which are involved in survival and fitness under a given condition by
22 simultaneously assaying the fitness of millions of mutants, thereby relating genotype to
23 phenotype and contributing to an understanding of bacterial cell biology. A recent
24 refinement of this approach allows the roles of essential genes in conditional stress survival
25 to be inferred by altering their expression. These advancements combined with the rapidly
26 falling costs of sequencing now allows comparisons between multiple experiments to
27 identify commonalities in stress responses to different conditions. This capacity however
28 poses a new challenge for analysis of multiple data sets in conjunction.

29

30 Results

31 To address this analysis need, we have developed 'AlbaTraDIS'; a software application for
32 rapid large-scale comparative analysis of TraDIS experiments that predicts the impact of
33 transposon insertions on nearby genes. AlbaTraDIS can identify genes which are up or down
34 regulated, or inactivated, between multiple conditions, producing a filtered list of genes for
35 further experimental validation as well as several accompanying data visualisations. We
36 demonstrate the utility of our new approach by applying it to identify genes used by
37 *Escherichia coli* to survive in a wide range of different concentrations of the biocide
38 Triclosan. AlbaTraDIS automatically identified all well characterised Triclosan resistance
39 genes, including the primary target, *fabI*. A number of new loci were also implicated in
40 Triclosan resistance and the predicted phenotypes for a selection of these were validated
41 experimentally and results showed high consistency with predictions.

42

43 Conclusions

44 AlbaTraDIS provides a simple and rapid method to analyse multiple transposon mutagenesis
45 data sets allowing this technology to be used at large scale. To our knowledge this is the

46 only tool currently available that can perform these tasks. AlbaTraDIS is written in Python 3
47 and is available under the open source licence GNU GPL 3 from
48 <https://github.com/quadram-institute-bioscience/albatradis>.

49 **Keywords**

50 Microbial bioinformatics, TraDIS, Tn-Seq, insertion site sequencing, NGS, comparative
51 analysis, Genotype-phenotype association.

52

53 Background

54

55 Bacteria can evolve and adapt very rapidly to a wide range of challenging conditions, for
56 example exposure to an antimicrobial. The ability of bacteria to survive antimicrobial stress
57 is of major importance because, if current trends continue, it is predicted that by 2050 10
58 million people will die annually due to anti-microbial resistance (1). Despite its importance,
59 interactions between antimicrobials and bacteria are only partially understood and most
60 knowledge has been gained from a relatively simple set of laboratory culture conditions.
61 Whilst the primary modes of action for most anti-microbials are known (2,3), secondary
62 modes of action are either less well known, or not explored at all. Mechanisms of
63 antimicrobial action and resistance in bacteria are complex and often vary depending on
64 growth phase and/or concentration of the antimicrobial applied. A notable example of this
65 has been described for the biocide Triclosan. Triclosan is a canonical fatty acid inhibitor
66 although against *Escherichia coli* it exerts a bacteriostatic effect at low concentrations but is
67 bactericidal at high concentrations (4). Additionally, understanding bacterial genotype-
68 phenotype associations in different environments and stress conditions might help to
69 maximise the promising health benefits from symbionts that are part of the human
70 microbiome.

71 Transposon mutagenesis is an empirical tool that can provide insights into mechanisms
72 involved in survival and fitness by simultaneously assaying the role of many genes under
73 different conditions. This works by testing millions of mutants of a bacterial strain in parallel
74 under various growth conditions. In this way information on gene essentiality, gene function
75 and genetic interactions under different growth conditions can be collected (5,6). There are
76 a number of techniques which are based on transposon mutagenesis and these include:
77 transposon sequencing (Tn-seq) (7); high-throughput insertion tracking by deep sequencing
78 (HITS) (8); insertion sequencing (INseq) (9); and transposon-directed insertion-site
79 sequencing (TraDIS) (6).

80 Transposon mutagenesis involves randomly inserting a transposon into a bacterium to
81 produce a mutant. On average there is a single insertion of the transposon sequence in each
82 bacterial cell. Some of these random insertions will disrupt gene function or expression,
83 which could potentially lead to changes in fitness (10). The mutant library can then be

84 grown in different conditions. In some cases, the insertion will disrupt systems that are
85 essential for life, and the bacterium will not grow (11). The corresponding gene can thus be
86 identified as being essential for life under the given conditions by its absence from the
87 mutant pool after growth. Likewise, when a single gene supports many insertions and
88 growth still occurs, that gene can be considered as non-essential for growth in that
89 condition.

90 Genes can be essential under one growth condition and non-essential in another. For
91 example, bacteria may be able to expel low concentrations of antimicrobials relatively
92 easily, but at high concentrations, above the minimum inhibitory concentration (MIC), may
93 require different detoxification mechanisms, regulated by a different set of genes, that only
94 become essential at high concentrations of the antimicrobial.

95 After exposure of the mutant library to any given condition, mutants are recovered and the
96 transposon and a small region of genomic material from mutants are extracted and
97 subjected to next-generation sequencing (12). The resulting sequence reads contain a short
98 segment of the transposon and at least 45 bases of the genome adjacent to the insertion.
99 These reads are aligned to an annotated reference genome, which allows the identification
100 of the position at which the transposon was inserted and the insertions to be associated
101 with specific genes and their functions. The primary output is a table of the frequencies of
102 insertions at each base in the reference genome. Results from test conditions are compared
103 with controls to identify conditionally important genes.

104 To date, one major barrier to the adoption of transposon mutagenesis for mechanistic
105 studies has been the complex nature of the protocols and the need for non-standard
106 sequencing instrument setups (12). These issues have been incrementally overcome which,
107 in conjunction with the rapidly falling costs of genome sequencing, has made transposon
108 mutagenesis an increasingly cost-effective method for screening millions of mutants
109 simultaneously under a large number of different conditions (5,13–16).

110 A limitation of the traditional TraDIS approach is, that essential genes cannot be effectively
111 assayed, as mutants with insertions in them will not grow. A recent modification of the
112 TraDIS protocol (17) (TraDIS+) allows the conditional fitness of all genes in the genome to be
113 assayed simultaneously, including essential genes. This methodology uses a transposon with
114 an outward directed inducible promoter allowing the impact of transcription alteration of
115 each gene to be assayed as well as gene inactivation. By comparing induced and uninduced

116 conditions a better 'signal-to-noise' ratio is achieved to identify genes where expression
117 changes contribute to conditional survival. Additionally, it is a suitable approach to identify
118 where 'knock-down' of expression of a gene can influence survival. Incorporating the ability
119 to alter expression of all the genes of an organism in one experimental condition in a
120 controlled manner promises to be hugely powerful, as applying changes to all genes in a
121 genome without prior knowledge about function has the potential to uncover a large
122 number of new genotype-phenotype relationships.

123 Analysis of the large-scale highly complex data resulting from experiments using transposon
124 mutagenesis can be a considerable challenge; analysis involves tens of millions of data
125 points (each corresponding to a physical bacterium), with controls and multiple replicates.
126 The interpretation of these data is thus complicated. Previous work has focused on
127 manually interpreting insert site patterns by comparing mutants with controls (18) or by
128 looking for simple signals that indicate whether a gene is essential for the survival of a
129 bacterium (16), or for its evolutionary fitness using tools such as Bio-TraDIS (12). However,
130 modes of action and any commonalities between different growth conditions are not
131 computationally identified within the existing Bio-TraDIS toolkit, and results must be
132 manually analysed. This is time consuming and limits the number of conditions that can be
133 compared. While the Bio-TraDIS toolkit identifies essential and non-essential genes as well
134 as performs comparison between one condition and control, it has little functionality for
135 filtering, prioritising and cross conditional comparison. In order to evaluate the putative
136 genes identified by the Bio-TraDIS toolkit, a visualisation tool, such as Artemis (19), must be
137 used to compare multiple replicates for a condition against controls. This requires prior
138 knowledge and experience to judge which inserts are most likely to be biologically
139 significant. Therefore, visualising all of the information from more than a single condition
140 becomes impractical due to the volume of information.

141 To address these issues, we present AlbaTraDIS, a software for rapid large-scale
142 comparative analysis of TraDIS experiments that predicts the impact of inserts on nearby
143 genes. It uses the statistical methods published in the Bio-TraDIS toolkit as a foundation. To
144 our knowledge this is the only tool currently available that can perform these tasks.
145 AlbaTraDIS is written in Python 3 and is available under the open source licence GNU GPL 3
146 from <https://github.com/quadram-institute-bioscience/albatradis>.

147


148 Implementation of AlbaTraDIS

149

150 In the main AlbaTraDIS workflow (albatradis script), as illustrated in Figure 1, we extend the
151 Bio-Tradis functionality to identify and analyse signals from data generated by the TraDIS+
152 method, which includes determining putative alteration of transcription of genes in the
153 forward or reverse complementary directions. The input to the albatradis script are insert
154 site plots along with the annotated reference genome in EMBL format (20). The insert site
155 files contain the number of insertions on the forward and reverse strands, at each base in
156 the genome. One or more growth conditions, and a matching number of controls, are
157 required as input, with a minimum of two replicates recommended to account for
158 experimental variation. To generate the insert site files, sequence reads generated using
159 Illumina sequencing, are aligned to a reference genome using Bio-Tradis.

160 The first step in the albatradis workflow is to apply normalisation in order to provide a more
161 consistent analysis in the presence of natural experimental variation, but this option can be
162 disabled if it is not desired. Each input file is normalised by the ratio of the number of
163 insertions in the input file to the maximum number of insertions across all files.

164 In order to screen the genome for different signals, by default, a reference-free sliding
165 window is used. The window size defaults to 50 bases, as this was found experimentally to
166 be the minimum window size where a signal could be detected with an insertion site density
167 of one insertion every ten bases. This can be increased, but the boundaries of an identified
168 mechanism become poorly defined, or may be missed entirely, if multiple mechanisms are
169 present within one window, cancelling each other out. Alternatively, there is an option for
170 an annotated reference-guided analysis. Each of the annotated genes and features are then
171 treated as windows.



172


173

174 **Figure 1: The underlying method for AlbaTraDIS.** The inputs are insert site plots, with a
175 frequency count of the insertions at each base in the genome for a condition and controls
176 and the annotated genome in EMBL format. The abundance of inserts are normalised and
177 the plots split into forward strand, reverse strand and combined strand insertions.
178 Essentiality and differential abundance is assessed using sliding windows or a per gene
179 option. The height of the log fold change plot indicates the log fold change difference in
180 insertions between the conditions and controls. The list of significant genes is compiled
181 using user definable values of corrected p value (q-value), logCPM and logFC.

182

183 Genes and Windows are annotated with their essentiality. An essential gene is a gene which
184 has no or very few insertions (no data points) as without the functioning gene, the bacteria
185 do not survive, and thus are not present in the resulting sequencing data from that
186 particular experiment (See Figure 2B). Essentiality analysis is performed using the method as
187 implemented in Bio-TraDIS (tradis_essentiality.R). A threshold value for the number of

188 insertions within essential genes is estimated using the observed bimodal distribution of
189 insertion sites over genes when normalized for gene length (5).
190 The log FC of each window, or gene, is overlaid onto the bases of the genome, producing
191 plot files for analysis of the forward, reverse and combined data, and visualisation in
192 applications such as Artemis (19).
193 If the sliding window option is used, short gaps are spanned automatically. This shows
194 where there is a strong increase or decrease of insertions in any part of the genome, and
195 whether it is in a single direction, or in both directions. This translates multiple signal spikes
196 into clearly delineated blocks with putative modes of action (See Figure 2A). Any regions of
197 the genome with blocks or genes above pre-defined levels (as previously noted) are selected
198 as loci that may have a putative role in sensitivity to the test conditions. Putative changes in
199 the numbers of mutants with insertions upstream or downstream of genes which may alter
200 transcription are strong indications that those genes are important in bacterial survival under
201 test conditions and also allows inferences about the importance of essential genes.



202

203 **Figure 2:** A) The top four lines are the insertion sites in controls and under treatment
204 conditions, where red lines are insertions in the forward direction and blue lines are
205 insertions in the reverse direction, with the height corresponding to the number mapped
206 reads identified for this site. The next three lines correspond to the signal identified by
207 AlbaTraDIS using a sliding window of 50 bases and an interval of 25 bases, with the height
208 corresponding to the log fold change between the treatments and controls. The bottom

209 section shows the genes as found in the reference genome, with the forward reading
210 frames of translation. B) The pattern of insertions around a gene that imply transcriptional
211 augmentation, in the forward or reverse complementary direction. The shape of the gene
212 indicates the direction, with the 5' at the beginning (flat end) and the 3' prime at the
213 pointed end. Insertions on the forward strand are above the line and insertions on the
214 reverse strand are below the line.

215

216 In order to identify insertions that may alter gene transcription as well as knockouts, the
217 insertions are divided into the forward and reverse inserts, giving three streams for analysis
218 (forward, reverse and combined). The aim is to identify significant changes in each sliding
219 window or gene between condition and control as described in (5) (See Figure 2B). This
220 analysis is based on methodology used for differential expression analysis as implemented
221 in edgeR (21), as the data is given as insertion counts per gene or genetic region and can
222 therefore be modelled by a negative binomial distribution. Therefore, the next step in the
223 albatradis workflow is calling the Bio-TraDIS toolkit (`tradis_comparison.R`) to perform
224 comparison of insertion abundances between control and condition. This comparison
225 comprises a normalisation of trimmed mean of M values (TMM) (22) and the calculation of
226 distribution parameters based on tag-wise dispersion estimates. The resulting distributions
227 for condition and control are then compared using an adopted exact test. P values are
228 corrected for multiple testing using the Benjamini-Hochberg method (23). A list of all
229 significant genes is produced. The user can specify parameters that mark significance, but as
230 a default a corrected P value (Q value) of < 0.05 , an absolute log fold change (log FC) of > 1 ,
231 and an absolute log count per million (log CPM) > 8 are considered significant. The produced
232 list also contains a summary of each statistically-significant gene, its classification (up/down
233 regulation, knockout), its coordinates, its maximum log FC, whether there is increased or
234 decreased expression, the direction of the signal (forward/reverse strain, or both) and the
235 upstream gene.


236

237 **Multiple condition comparison**

238

239 The albatradis main workflow compares replicates of one control and one condition. Often
240 there are many different conditions and/or timepoints. Aiming to give a more complete

241 picture of what happens, it is of interest to compare the different conditions/timepoints in
242 order to identify commonalities. The `albatradis-presence_absence` script summarises and
243 performs comparative analysis of the outputs from the `albatradis` workflow. The impact of
244 each test condition on each gene can be observed. Changes in essentiality of genes are
245 compared with the control (i.e., where essential genes become non-essential and where
246 non-essential genes become essential). All of these methods are designed to allow scaling
247 up and automation of the TraDIS analysis. The input to the script are multiple *gene reports*,
248 representing various test conditions and the annotated genome (embl format). A variety of
249 outputs is produced: the union and intersection of the genes for the test conditions which
250 allows for further analysis of commonalities, a global heatmap of the log FC observed
251 between the conditions and the controls and a spreadsheet representing the heatmap data.
252 Common patterns can be represented by a tree structure, grouping common biological
253 modes of action together. Two trees are created, one using hierarchical clustering
254 (dendrogram) and one using the neighbour-joining method. Both trees are supplied in
255 *Newick* format (<http://evolution.genetics.washington.edu/phylip/newicktree.html>) and can
256 be viewed using a visualisation program like FigTree (24) (See Figure 3A).



257
258 **Figure 3:** A) Neighbour joining tree of the presence and absence of genes that have
259 significant differences in the number of insertions compared with the control after exposure
260 to different concentrations of Triclosan. This shows how similar different conditions relate
261 to each other based on their modes of action. B) Example network of the relatedness of

262 different modes of action where the green nodes are different conditions (such as drug
263 concentrations), and the grey nodes are a single gene.

264

265 A graphical representation of the collection of genes under different conditions is provided.
266 Genes and conditions are represented as nodes in the graph. Where AlbaTraDIS has
267 identified a link between a test condition and a gene, an edge is added, which is weighted
268 by the number of identified connections. Figure 3B gives an example of such a network. The
269 grey nodes represent genes and the green nodes represent test conditions. This allows for
270 interrogation of commonalities between conditions using standard graph theory algorithms.
271 If there are no genes in common amongst the conditions, the graph consists of several
272 disconnected subgraphs.

273

274 Results

275 Experimental data used to evaluate usefulness of AlbaTraDIS

276 To evaluate the performance of AlbaTraDIS, it was used to analyse a dataset from TraDIS+
277 experiments of *E. coli* grown in different concentrations of the antibacterial agent, Triclosan.
278 This showed that large scale analysis was possible and confirmed the identity of known
279 modes of action. A full description of this dataset is given in the companion article (17); this
280 is the first dataset of this scale to be published. We briefly summarise the experiments and
281 the data collected.


282 Triclosan is an antibacterial agent that has been widely used in clinical practice and in
283 cleaning and domestic hygiene products (25). It is known to exhibit concentration
284 dependent effects; at low concentrations it is bacteriostatic (inhibits growth) and
285 bactericidal (kills) at high concentrations (25,26). However, the mechanisms for these
286 modes of action are not well understood, with only one primary target well validated (25).
287 TraDIS was used to gain a better understanding of the consequences of exposure to
288 Triclosan at different concentrations with *E. coli* BW25113 (27). This bacterium was chosen
289 because it is well characterised laboratory strain with a fully sequenced genome. *E. coli*
290 BW25113 is also the parent strain of the Keio collection (28), for which every gene in the
291 genome has been systematically knocked out, allowing for subsequent experimental
292 validation of phenotype. A library of around half a million mutants was generated from *E.*

293 *coli* BW25113 using a transposon that contained an inducible outward directed promoter.
294 The promoter allowed for enhanced expression with Isopropyl β -D-1-thiogalactopyranoside
295 (IPTG). The mutant library was then grown for 24 hours in eight concentrations of Triclosan
296 (from 0.008 to 1 mg/L) and in combination of three concentrations of the inducer to give a
297 spectrum of promoter expression. There were two controls and two technical replicates,
298 resulting in 60 individual TraDIS experiments. Table 1 provides the accession numbers for
299 data collected and the conditions evaluated (Triclosan concentrations) for each experiment.
300 The genome of *E. coli* BW25113 (accession number GCA_000750555.1) (27) consists of
301 4,631,469 bases in a single chromosome with 4,774 annotated genes.

302

303 Ability of AlbaTraDIS to identify primary modes of action

304 To confirm that the results from AlbaTraDIS are accurate, we used it to evaluate the
305 Triclosan dataset for *E. coli* BW25113 as listed in Table 1. We looked for the presence of
306 genes that are known from experimental validation to be important in the action of
307 Triclosan, and also important in bacterial resistance to Triclosan. The primary target of
308 Triclosan is the enzyme FabI. Mutation or over-expression of *fabI* are known mechanisms of
309 resistance to Triclosan (25). Whilst *fabI* is essential, and therefore not assayed by traditional
310 transposon mutagenesis approaches, inserts upstream of *fabI* at the 5' end were clearly
311 identified by AlbaTraDIS. An induction of *fabI* was classified as beneficial for survival when
312 grown in Triclosan (Figure 4). Other genes known to be involved in resistance were also
313 identified including the efflux and regulators *acrR*, *acrB*, *marR*, *soxS*, and many genes
314 involved in generation of lipopolysaccharide. A number of loci not known previously to be
315 involved in Triclosan resistance were also identified. The predicted phenotypes for a
316 selection of these were validated by using the corresponding knockout mutants from the
317 Keio library, growing them in different Triclosan concentrations for 24h and assessing their
318 growth rate in comparison to the parent strain BW25113. The results showed high
319 consistency with predictions. As previously mentioned, more details on these results and
320 other biological outcomes as well as methodology can be found in the companion paper
321 (17).



322
323

324 **Figure 4:** The top 4 panels show the transposon insertion sites, 2 controls and 2 for libraries
325 grown in 0.5 mg/L triclosan. The next three lines correspond to the signal identified by
326 AlbaTraDIS using a with the height corresponding to the log fold change between the
327 treatments and controls. There is an increase in insertions in the promotor area (upstream)
328 in the direction towards the gene, which indicates that up-regulation of *fabI* in *E. coli* grown
329 in 0.5 mg/L of Triclosan might be beneficial to survival. This shows that AlbaTraDIS can
330 identify the primary target of Triclosan.

331

332 Computational Environment


333 All of the computational experiments were performed on the MRC CLIMB framework (30),
334 using the Genomics Virtual Laboratory (v4.2) (31). The operating system was Ubuntu 16.10
335 LTS and the resources available were four processors and 32 Giga Bytes (GB) of memory.
336 Resources of this scale are not required to run AlbaTraDIS, these were merely the default

337 minimum available. AlbaTraDIS version 0.0.5 running on Python version 3.6.7 and Bio-
338 TraDIS version 1.4.1 (12) running on Perl version 5.22.1 were used. Experimental running
339 times and peak memory usage were measured using the time command.

340

341 Performance of AlbaTraDIS

342 The scalability of AlbaTraDIS was evaluated by varying the number of test conditions
343 included in the analysis using the data and computing resources described. As the number
344 of test conditions increased the total running time of the main AlbaTraDIS workflow
345 increased linearly (See Figure 5) which matched the theoretical runtime ($O(n)$). However,
346 the most resource-intensive part of the process can be parallelised, and runtime is constant
347 when the number of processors equal the number of test conditions. The condition
348 comparisons running time, while also linear, was negligible. As an indication of the overall
349 running time, the full dataset described previously took 74 minutes when run with a single
350 processor. This is likely to vary with the available computing resources and datasets.



351

352 **Figure 5:** The total running time, including comparative analysis, for varying numbers of test
353 conditions when using a single CPU (Blue) and the total memory usage in GB, including
354 comparative analysis, for varying numbers of conditions when using a single CPU (Grey).

355

356 The total memory usage (See Figure 5) remained constant but will vary with different
357 datasets. When 1 processor was available for each condition ($n=8$), the total running time

358 was just 9.4 minutes. The memory requirement was 2.1 GB for eight conditions, which is
359 low enough that it can be run on a standard desktop machine. We were able to achieve
360 these results by using Cython (32) is used internally for computationally-intensive parts of
361 the method, allowing for native C-compiled code to be used within Python.

362

363 Conclusions

364 AlbaTraDIS allows the analysis of large-scale transposon insertion sequencing experiments
365 to be performed and results compared across conditions than had previously been possible.
366 In addition, the context of inserts in relation to local genes and their impacts can be
367 predicted which greatly reduces the complexity of the analysis required for large data sets.
368 Comparative analysis of the results from a range of experimental conditions allows
369 identification of common modes of action. Known mechanisms of resistance were efficiently
370 identified, including those where expression changes were important. AlbaTraDIS is fast,
371 scalable and can be run on standard desktop machines.

372

373 Availability and requirements

374 **Project name:** AlbaTraDIS

375 **Project home page:** <https://github.com/quadram-institute-bioscience/albatradis>

376 **Operating system(s):** Linux, OSX

377 **Programming language:** Python version 3.3+

378 **Other requirements:** Bio-TraDIS toolkit

379 **License:** GNU GPL version 3

380 **Any restrictions to use by non-academics:** GNU GPL version 3

381 The software can be installed using *conda* (33), *pip* (<https://pypi.org>) or as a Docker
382 container (34).

383

384 List of Abbreviations

385 GMI: Global Microbial Identifier

386 IPTG: Isopropyl β -D-1-thiogalactopyranoside

387 NGS: Next Generation Sequencing

388 TraDIS: Transposon Directed Insertion-site Sequencing

389 MIC: Minimum Inhibitory Concentration

390 TMM: Trimmed Mean of M values

391 CPM: Count Per Million

392 FC: Fold Change

393 GB: Giga Bytes

394

395 **Table 1:** Conditions evaluated (Triclosan concentrations) and accession numbers for each
396 experiment. The overall project accession number is PRJEB29311.

397

Triclosan (mg/L)	Accession number for experiment	
	Replicate 1	Replicate 2
0.008	ERR2854367	ERR2854368
0.015	ERR2854369	ERR2854370
0.03	ERR2854371	ERR2854372
0.06	ERR2854373	ERR2854374
0.125	ERR2854375	ERR2854376
0.25	ERR2854377	ERR2854378
0.5	ERR2854379	ERR2854380
1.0	ERR2854381	ERR2854382
Control 1	ERR2854363	ERR2854364
Control 2	ERR2854365	ERR2854366

398

399

400 **Declarations**

401

402 **Ethics approval and consent to participate**

403 Not applicable.

404

405 **Consent for publication**

406 Not applicable.

407

408 [Availability of data and material](#)

409 The datasets generated and/or analysed during the current study are available without
410 restriction from the European Nucleotide Archive at EMBL-EBI and accession numbers for
411 the raw data are listed in Supplementary.

412

413 [Competing interests](#)

414 No competing interests.

415

416 [Funding](#)

417 AJP and TLV were supported by the Quadram Institute Bioscience BBSRC funded Core
418 Capability Grant (project number BB/CCG1860/1). KAT, SB, MY, MAW and IGC were
419 supported by the BBSRC Institute Strategic Programme Microbes in the Food Chain
420 BB/R012504/1 and its constituent project BBS/E/F/000PR10349. The funders had no role in
421 study design, data collection and analysis, decision to publish, or preparation of the
422 manuscript.

423

424 [Authors' contributions](#)

425 AJP wrote the software and wrote the manuscript.

426 SB contributed to the software and the manuscript.

427 TLV packaged the software for general use.

428 KAT, MY performed the microbiology experiments and interpreted the results.

429 GMS, MAW, IGC provided overall study design and guidance.

430 All authors have read and contributed to the manuscript.

431

432 [Acknowledgements](#)

433 We thank Andrea Telatin and Marianne Defernez for their involvement in this project and

434 Lars Barquist for providing the Bio-TraDIS toolkit.

435

436 References

437

- 438 1. O'Neil J. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis
439 for the Health and Wealth of Nations 2014. 2014.
- 440 2. Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: A
441 guide for clinicians. *J Anaesthesiol Clin Pharmacol*. 2017;33(3):300–5.
- 442 3. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. *J Appl Microbiol*.
443 2002 May;92(s1):55S–64S.
- 444 4. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the
445 most important agents for scrubs and rubs. *Clin Microbiol Rev*. 2004 Oct;17(4):863–93,
446 table of contents.
- 447 5. Dembek M, Barquist L, Boinett CJ, Cain AK, Mayho M, Lawley TD, et al. High-Throughput
448 Analysis of Gene Essentiality and Sporulation in *Clostridium difficile*. *mBio*. 2015 May
449 1;6(2):e02383-14.
- 450 6. Langridge GC, Phan M-D, Turner DJ, Perkins TT, Parts L, Haase J, et al. Simultaneous
451 assay of every *Salmonella* Typhi gene using one million transposon mutants. *Genome*
452 *Res*. 2009 Dec;19(12):2308–16.
- 453 7. van Opijnen T, Bodi KL, Camilli A. Tn-seq: high-throughput parallel sequencing for fitness
454 and genetic interaction studies in microorganisms. *Nat Methods*. 2009 Oct;6(10):767–
455 72.
- 456 8. Gawronski JD, Wong SMS, Giannoukos G, Ward DV, Akerley BJ. Tracking insertion
457 mutants within libraries by deep sequencing and a genome-wide screen for
458 *Haemophilus* genes required in the lung. *Proc Natl Acad Sci U S A*. 2009 Sep
459 22;106(38):16422–7.
- 460 9. Goodman AL, McNulty NP, Zhao Y, Leip D, Mitra RD, Lozupone CA, et al. Identifying
461 genetic determinants needed to establish a human gut symbiont in its habitat. *Cell*
462 *Host Microbe*. 2009 Sep 17;6(3):279–89.
- 463 10. Elena SF, Ekuwe L, Hajela N, Oden SA, Lenski RE. Distribution of fitness effects caused
464 by random insertion mutations in *Escherichia coli*. *Genetica*. 1998 Mar 1;102(0):349.
- 465 11. Salama NR, Shepherd B, Falkow S. Global Transposon Mutagenesis and Essential Gene
466 Analysis of *Helicobacter pylori*. *J Bacteriol*. 2004 Dec 1;186(23):7926–35.
- 467 12. Barquist L, Mayho M, Cummins C, Cain AK, Boinett C, Page AJ, et al. The TraDIS toolkit:
468 sequencing and analysis for dense transposon mutant libraries. *Bioinformatics*.
469 2016;btw022.

- 470 13. Boinett CJ, Cain AK, Hawkey J, Do Hoang NT, Khanh NNT, Thanh DP, et al. Clinical and
471 laboratory-induced colistin-resistance mechanisms in *Acinetobacter baumannii*.
472 *Microb Genomics*. 2019 Feb 5;
- 473 14. Ruiz L, Bottacini F, Boinett CJ, Cain AK, O'Connell-Motherway M, Lawley TD, et al. The
474 essential genomic landscape of the commensal *Bifidobacterium breve* UCC2003. *Sci*
475 *Rep*. 2017 Jul 17;7(1):5648.
- 476 15. Zhu L, Charbonneau ARL, Waller AS, Olsen RJ, Beres SB, Musser JM. Novel Genes
477 Required for the Fitness of *Streptococcus pyogenes* in Human Saliva. *mSphere*. 2017
478 Nov 1;2(6).
- 479 16. Vohra P, Chaudhuri RR, Mayho M, Vrettou C, Chintoan-Uta C, Thomson NR, et al.
480 Retrospective application of transposon-directed insertion-site sequencing to
481 investigate niche-specific virulence of *Salmonella* Typhimurium in cattle. *BMC*
482 *Genomics*. 2019 Jan 8;20(1):20.
- 483 17. Yasir M, Turner AK, Bastkowski S, Page AJ, Telatin A, Phan MD, Monahan L, Darling A,
484 Webber MA, Charles IG. A new massively-parallel transposon mutagenesis approach
485 comparing multiple datasets identifies novel mechanisms of action and resistance to
486 triclosan.
- 487 18. Cowley LA, Low AS, Pickard D, Boinett CJ, Dallman TJ, Day M, et al. Transposon Insertion
488 Sequencing Elucidates Novel Gene Involvement in Susceptibility and Resistance to
489 Phages T4 and T7 in *Escherichia coli* O157. *mBio*. 2018 Jul 24;9(4).
- 490 19. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA. Artemis: an integrated
491 platform for visualization and analysis of high-throughput sequence-based
492 experimental data. *Bioinformatics*. 2012 Feb 15;28(4):464–9.
- 493 20. Embl format. Available from: <ftp://ftp.ebi.ac.uk/pub/databases/embl/doc/usrman.txt>
- 494 21. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq
495 experiments with respect to biological variation. *Nucleic Acids Res*. 2012
496 May;40(10):4288–97.
- 497 22. Robinson MD, Oshlack A. A scaling normalization method for differential expression
498 analysis of RNA-seq data. *Genome Biol*. 2010 Mar 2;11(3):R25.
- 499 23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
500 Approach to Multiple Testing. *J R Stat Soc Ser B Methodol*. 1995;57(1):289–300.
- 501 24. Andrew Rambaut AR. FigTree, version 1.4.3 [Internet]. 2009. Available from:
502 <http://tree.bio.ed.ac.uk/software/figtree>
- 503 25. Russell AD. Whither triclosan? *J Antimicrob Chemother*. 2004 May 1;53(5):693–5.
- 504 26. Bailey AM, Constantinidou C, Ivens A, Garvey MI, Webber MA, Coldham N, et al.
505 Exposure of *Escherichia coli* and *Salmonella enterica* serovar Typhimurium to triclosan

- 506 induces a species-specific response, including drug detoxification. *J Antimicrob*
507 *Chemother.* 2009 Nov;64(5):973–85.
- 508 27. Grenier F, Matteau D, Baby V, Rodrigue S. Complete Genome Sequence of *Escherichia*
509 *coli* BW25113. *Genome Announc.* 2014 Oct 16;2(5).
- 510 28. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, et al. Construction of
511 *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol*
512 *Syst Biol* [Internet]. 2006 Feb;2. Available from: <https://doi.org/10.1038/msb4100050>
- 513 29. Xu HH, Real L, Bailey MW. An array of *Escherichia coli* clones over-expressing essential
514 proteins: a new strategy of identifying cellular targets of potent antibacterial
515 compounds. *Biochem Biophys Res Commun.* 2006 Nov 3;349(4):1250–7.
- 516 30. Connor TR, Loman NJ, Thompson S, Smith A, Southgate J, Poplawski R, et al. CLIMB (the
517 Cloud Infrastructure for Microbial Bioinformatics): an online resource for the medical
518 microbiology community. *Microb Genomics.* 2016;2(9):e000086.
- 519 31. Afgan E, Sloggett C, Goonasekera N, Makunin I, Benson D, Crowe M, et al. Genomics
520 Virtual Laboratory: A Practical Bioinformatics Workbench for the Cloud. *PLoS One.*
521 2015;10(10):e0140829.
- 522 32. Behnel S, Bradshaw R, Citro C, Dalcin L, Seljebotn DS, Smith K. Cython: The Best of Both
523 Worlds. *Comput Sci Eng.* 2011 Apr;13(2):31–9.
- 524 33. Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH, et al. Bioconda:
525 sustainable and comprehensive software distribution for the life sciences. *Nat*
526 *Methods.* 2018 Jul;15(7):475–6.
- 527 34. Merkel D. Docker: Lightweight Linux Containers for Consistent Development and
528 Deployment. *Linux J.* 2014 Mar;2014(239).
- 529
530